Tokyo giant to acquire England's Arakis

Sosei will buy Cambridge, UK-based biopharma Arakis -- a 2005 Fierce 15 winner -- for £106.5 million, the companies announced. The buyout comes on the heels of Novartis' decision to develop one of Arakis' products into a treatment for smoker's cough. Arakis has three other products in clinical development, including a cancer pain drug that will enter Phase III trials later this year.

- read this Business Weekly story for more

Suggested Articles

Rachel Humphrey, M.D., who joined CytomX as chief medical officer after heading immuno-oncology at AstraZeneca and Eli Lilly, has made her exit.

Scientists have discovered a scorpion toxin could inspire treatments to block the inflammation that triggers chronic pain.

The phase 2 success keeps Hal Barron’s group on track to file for approval in multiple myeloma by the end of the year.